Cargando…
Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study
BACKGROUND: Chronic migraine (CM) is associated with substantial economic burden. Real-world data suggests that onabotulinumtoxinA treatment for CM reduces healthcare resource utilisation (HRU) and related costs. METHODS: REPOSE was a 2-year prospective, multicentre, non-interventional, observationa...
Autores principales: | Kollewe, Katja, Gaul, Charly, Gendolla, Astrid, Sommer, Katherine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173963/ https://www.ncbi.nlm.nih.gov/pubmed/34078259 http://dx.doi.org/10.1186/s10194-021-01260-4 |
Ejemplares similares
-
An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study
por: Ahmed, Fayyaz, et al.
Publicado: (2019) -
Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
por: Eren, Ozan E., et al.
Publicado: (2020) -
Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data
por: Davies, Brendan, et al.
Publicado: (2017) -
Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020) -
OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023)